|The 2018 Lake Louise Acute Mountain Sickness Score|
RC Roach, PH Hackett, O Oelz, P Bärtsch, AM Luks, MJ MacInnis, ...
High altitude medicine & biology 19 (1), 4-6, 2018
|MET is required for the recruitment of anti-tumoural neutrophils|
V Finisguerra, G Di Conza, M Di Matteo, J Serneels, S Costa, ...
Nature 522 (7556), 349-353, 2015
|Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice|
SR Walmsley, ER Chilvers, AA Thompson, K Vaughan, HM Marriott, ...
The Journal of clinical investigation 121 (3), 1053-1063, 2011
|Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial|
JK Baillie, AAR Thompson, JB Irving, MGD Bates, AI Sutherland, ...
QJM 102 (5), 341-348, 2009
|Hypoxia selectively inhibits respiratory burst activity and killing of Staphylococcus aureus in human neutrophils|
NN McGovern, AS Cowburn, L Porter, SR Walmsley, C Summers, ...
The Journal of Immunology 186 (1), 453-463, 2011
|Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude|
JK Baillie, MGD Bates, AAR Thompson, WS Waring, RW Partridge, ...
Chest 131 (5), 1473-1478, 2007
|Hypoxia-inducible factor 2α regulates key neutrophil functions in humans, mice, and zebrafish|
AAR Thompson, PM Elks, HM Marriott, S Eamsamarng, KR Higgins, ...
Blood 123 (3), 366-376, 2014
|Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro|
SJ Jackson, J Varley, C Sellers, K Josephs, L Codrington, G Duke, ...
High Altitude Medicine & Biology 11 (3), 217-222, 2010
|Change in plasma vascular endothelial growth factor during onset and recovery from acute mountain sickness|
DA Dorward, AA Roger Thompson, J Kenneth Baillie, M MacDougall, ...
Respiratory medicine 101 (3), 587-594, 2007
|Mechanical activation of hypoxia-inducible factor 1α drives endothelial dysfunction at atheroprone sites|
S Feng, N Bowden, M Fragiadaki, C Souilhol, S Hsiao, M Mahmoud, ...
Arteriosclerosis, thrombosis, and vascular biology 37 (11), 2087-2101, 2017
|Sildenafil Citrate for the Prevention of High Altitude Hypoxic Pulmonary Hypertension: Double Blind, Randomized, Placebo-Controlled Trial|
MGD Bates, AAR Thompson, JK Baillie, AI Sutherland, JB Irving, N Hirani, ...
High Altitude Medicine & Biology 12 (3), 207-214, 2011
|Targeting vascular remodeling to treat pulmonary arterial hypertension|
AAR Thompson, A Lawrie
Trends in molecular medicine 23 (1), 31-45, 2017
|Network analysis reveals distinct clinical syndromes underlying acute mountain sickness|
DP Hall, IJC MacCormick, AT Phythian-Adams, NM Rzechorzek, ...
PloS one 9 (1), e81229, 2014
|Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses|
P Sadiku, JA Willson, RS Dickinson, F Murphy, AJ Harris, A Lewis, ...
The Journal of Clinical Investigation 127 (9), 3407-3420, 2017
|Hypoxia, the HIF pathway and neutrophilic inflammatory responses|
AA Thompson, J Binham, T Plant, MKB Whyte, SR Walmsley
Biological chemistry 394 (4), 471-477, 2013
|HIF-mediated innate immune responses: cell signaling and therapeutic implications|
AJ Harris, AAR Thompson, MKB Whyte, SR Walmsley
|Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis|
EE McGrath, A Lawrie, HM Marriott, P Mercer, SS Cross, N Arnold, ...
Thorax 67 (9), 796-803, 2012
|Hypoxia determines survival outcomes of bacterial infection through HIF-1α–dependent reprogramming of leukocyte metabolism|
AAR Thompson, RS Dickinson, F Murphy, JP Thomson, HM Marriott, ...
Science Immunology 2 (8), eaal2861, 2017
|Endothelial nitric oxide synthase polymorphisms do not influence pulmonary artery systolic pressure at altitude|
EMD Smith, JK Baillie, AAR Thompson, JB Irving, D Porteous, DJ Webb
High altitude medicine & biology 7 (3), 221-227, 2006
|Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema.|
MG Bates, AA Thompson, JK Baillie
Current opinion in investigational drugs (London, England: 2000) 8 (3), 226-231, 2007